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ABSTRACT 23 
This systematic review provides an overview of publications concerning pharmacogenetic 24 
research in pediatric patients with medulloblastoma and low-grade glioma. Three electronic 25 
databases searches including a manual search were performed to identify studies investigating 26 
potential interactions between germline variants and chemotherapy efficacy and toxicity. Of 27 
3,570 citations, twenty-one studies were included. Outcomes include overall survival, 28 
progression-free survival and treatment related adverse events (N = 5), cisplatin-induced 29 
ototoxicity (N = 13) and vincristine-induced neurotoxicity (N = 3). This review shows that the 30 
number of pharmacogenetic studies in well-defined pediatric brain tumor cohorts is poor and 31 
studies often report conflicting results. Large-scale international collaborations allowing 32 
analysis of sufficiently sized cohorts are therefore very important for the future of personalized 33 
medicine in brain tumors.   34 
INTRODUCTION 35 
Brain tumors are the most common solid malignancies of childhood, with incidence rates of 3-36 
5 per 100,000 children per year in the western population.[1, 2] The majority of pediatric brain 37 
tumors are low-grade gliomas and medulloblastomas.[3] Low-grade gliomas (WHO-38 
classification grade I and II) derive from glial cells in the central nervous system and are 39 
considered less aggressive with favorable survival rates of 85-95%.[4] Medulloblastomas are 40 
primary neuroectodermal tumors with survival rates varying between 30% and 80%, depending 41 
on risk group and age.[5-9] Despite these types of brain tumors to be clinically very different, 42 
they are treated with comparable chemotherapeutic regimens, including the cornerstone 43 
agents cisplatin, carboplatin, vincristine and cyclophosphamide. Unfortunately, brain tumor 44 
patients often suffer from long term sequelae partly due to tumor specific features like location 45 
and size, and partly due to treatment related side effects.  46 
Chemotherapy made it possible in several treatment protocols to postpone radiotherapy or 47 
decrease its dose or target volume, thereby decreasing radiotherapy side effects and, 48 
furthermore, increase survival.[10, 11] Despite the advances of chemotherapy, patients show 49 
a great variety in response to chemotherapeutic agents. Not only concerning anti-tumor effect, 50 
but also in the development and severity of toxicities. Chemotherapy-related side effects play 51 
a major role in reduced quality of life.[12] The most disabling long-term side effects caused by 52 
the chemotherapy include ototoxicity, nephrotoxicity, decreased cognitive functions and 53 
neurotoxicity.[13, 14] Ototoxicity is most often caused by treatment with cisplatin or carboplatin, 54 
which can result in an impairment of daily functioning and cognitive development.[15, 16] In 55 
addition, these platinum-based agents can, especially when combined with 56 
cyclophosphamide, lead to an increased risk of nephrotoxicity. Vincristine, a drug commonly 57 
used in pediatric cancer practice, is known to induce serious peripheral neurotoxicity during 58 
treatment. Severe toxicities are still often a reason for chemotherapy dose adjustments, which 59 
leads to a reduction of the desired anti-tumor effect and, consequently, might influence 60 
treatment efficacy.  61 
Efforts have been made to reduce the toxic side effects of chemotherapy in children to prevent 62 
them from long-term sequelae. For example, amifostine addition may be protective against 63 
cisplatin-induced ototoxicity.[17, 18] However, due to the lack of large randomized controlled 64 
trials testing its protective effect and a meta-analysis reporting no statistically significant 65 
results, amifostine is not included in clinical guidelines.[19] Clinical differences, e.g. age and 66 
cumulative chemotherapy dose, are known to play a role in the variable response to 67 
chemotherapy, but do not sufficiently predict the occurrence of severe side effects.[20, 21] For 68 
this reason, no clinical or biological markers for chemotherapy response are available for 69 
upfront stratification of patients with a brain tumor. Gaining more insight in the cause of the 70 
variations in response to chemotherapy and being able to predict response might help to 71 
optimize chemotherapeutic treatment for these patients and might prevent them from low 72 
treatment efficacy and drug-related adverse events. A tool to gain this insight is 73 
pharmacogenetics.  74 
Pharmacogenetic studies aim to identify inherited germline genetic markers that are 75 
associated with drug response, including treatment efficacy and drug-related adverse events. 76 
Associations found in pharmacogenetic research can be used for creating predictive models, 77 
offering tailored therapy and might thereby lead to improved survival and prevention from 78 
severe toxicities. This study field has already shown promising results in oncology patients. 79 
For example, multiple pharmacogenetic studies have shown a link between variants in the 80 
DPYD gene and high risk of severe toxicities during treatment with fluoropyrimidines, one of 81 
the most frequently prescribed group of anticancer drugs.[22-24] In the field of pediatric 82 
oncology, genetic variants associated with the outcome of acute lymphoblastic leukemia (ALL) 83 
are extensively investigated. An example is the role of polymorphisms in the glutathione-S 84 
transferase family, e.g. GSTM1, in the response to chemotherapy in treatment of ALL.[25] 85 
Pharmacogenetic studies have been published investigating patients with other types of 86 
cancer being exposed to the same chemotherapeutic agents as brain tumor patients, e.g. 87 
vincristine in ALL patients.[26] However from a pharmacogenetic view, brain tumors distinguish 88 
themselves from other pediatric cancers because of the presence of multiple possible 89 
confounding factors. These factors may include for example hearing loss secondary to cranial 90 
radiotherapy and decreased cognitive function as a result of tumor localization and size. Also, 91 
chemotherapeutic regimens (including cumulative dose) do often vary depending on the type 92 
of cancer. Therefore, it might be difficult to directly translate the findings to other (pediatric) 93 
cancer patients to brain tumor patients.   94 
This systematic review is a collection of pharmacogenetic studies investigating the response 95 
to chemotherapy in pediatric patients with a medulloblastoma or low-grade glioma.  This review 96 
provides an overview of the current state of studies in this research area and may present a 97 
more distinct lead for future studies.  98 
MATERIALS AND METHODS 99 
Studies were included if they investigated associations between germline polymorphisms and 100 
treatment outcome of chemotherapy in medulloblastoma and low-grade glioma patients. The 101 
cornerstone agents used in current treatment regimens, being cisplatin, carboplatin, vincristine 102 
and cyclophosphamide, plus the additional agents etoposide and lomustine were included in 103 
the search. Treatment outcome was defined as chemotherapy efficacy, being overall survival 104 
(OS) or progression free survival (PFS), or chemotherapy-related toxicity. Studies investigating 105 
the mentioned chemotherapeutic agents in heterogeneous cohorts with multiple pediatric 106 
cancers including brain tumors were also selected. Studies in patients with an anaplastic 107 
glioma (grade III) or glioblastoma (grade IV) were excluded, because of treatment regimens 108 
with other chemotherapeutic agents.  109 
The electronic databases MEDLINE, Embase, and Cochrane Library were systematically 110 
searched for relevant publications without limitations concerning publication dates. This was 111 
performed with the help of a medical librarian. The date of search was 30th of October, 2016. 112 
Detailed search terms are presented in Supplementary Table 1. Two reviewers (MK and MC) 113 
independently screened the list of citations for eligible articles. Potential citations were 114 
reviewed by their titles; selected titles were reviewed by abstract and, if the abstract was 115 
eligible, by full-text. After systematic screening, the reference lists of the included articles were 116 
manually screened for additional potential articles that may have been missed with the initial 117 
search strategy. Discrepancies between the two reviewers concerning eligibility of the studies 118 
did not occur. Case reports, conference abstracts and articles not written in English were 119 
excluded, as well as studies investigating associations with genetic variants in tumor cells.    120 
RESULTS 121 
The systematic search yielded a total of 3,570 unique citations, of which twenty-one studies 122 
were included in the review (Figure 1). The majority of the included studies used a candidate 123 
gene approach. Also, one pathway approach study and one genome-wide association study 124 
(GWAS) were identified. Pharmacogenetic studies regarding carboplatin, cyclophosphamide, 125 
etoposide and lomustine were not found. The included studies could be sorted into three 126 
categories; studies investigating the role of variants in overall treatment outcome of patients 127 
with brain tumors and studies specifically looking into relations between inherited variants and 128 
cisplatin-induced ototoxicity and vincristine-induced neurotoxicity. Here, the results of these 129 
studies will be presented and described by category. 130 
 131 
Pharmacogenetics and overall treatment outcome 132 
Five out of the twenty-one included studies focused on the role of pharmacogenetics with 133 
overall treatment outcome of chemotherapy in patients with medulloblastoma or low-grade 134 
glioma. Most studies investigated the influence of variations in specific genes on survival and 135 
presence of adverse events during treatment. It is important to note that treatment efficacy, 136 
e.g. OS and PFS, is not only determined by the chemotherapeutic treatment, but also by 137 
clinical variables, intrinsic tumor characteristics and other treatment facets. Despite this fact, 138 
survival is often used as an endpoint in pharmacogenetic studies into chemotherapy outcome 139 
to assess the overall impact of a genetic variation on treatment efficacy. When a study is 140 
performed with candidate genes that are known to influence specific drug pharmacokinetics 141 
and -dynamics, one may suspect a relation between this genetic variant and a significant 142 
difference in treatment outcome.  Details of the included studies are visualized in Table 1, 143 
which shows that these candidate approach studies have mainly investigated detoxification 144 
genes.  145 
Genetics variants in members of the glutathione S-transferase (GST) family are investigated 146 
in three studies, focusing on the relation of these variants with OS, PFS and risk of drug-related 147 
adverse events in brain tumor patients.[27-29] GST polymorphisms were studied because the 148 
enzymes encoded by these genes have a known function in detoxification of several types of 149 
chemotherapy, including alkylating and platinum agents, which are used in brain tumor 150 
treatment. A study in 42 medulloblastoma patients reported associations with both GSTM1 and 151 
GSTT1 null genotypes and any ≥grade 3 toxicity (including myelosuppression, neurotoxicity, 152 
ototoxicity and nephrotoxicity) and intellectual impairment.[28] Variants in GST pi 1 (GSTP1) 153 
were studied in 106 medulloblastoma/PNET patients, identifying the variant GSTP1 105A>G 154 
to be significantly associated with hearing loss.[29] The mentioned associations in GST were 155 
not identified in an earlier study in a large cohort of various primary malignant gliomas (n=278, 156 
which consisted of forty-four low-grade gliomas, but zero medulloblastomas).[27] Replication 157 
studies concerning these associations in brain tumor patients have not appeared. No 158 
significant associations between variants in GST and PFS or OS were found in these studies.   159 
 160 
Pharmacogenetics and cisplatin-induced ototoxicity 161 
Thirteen papers reported on pharmacogenetics concerning cisplatin-induced hearing loss, 162 
including one GWAS, in a total of 649 brain tumor patients. An overview of the published 163 
articles is provided in Table 2. The first published pharmacogenetic studies investigating 164 
cisplatin-induced ototoxicity in brain tumor patients were small-sized candidate approach 165 
studies in mixed cohorts of pediatric cancer patients.[30-33] Several GST variants were 166 
studied by Peters et al., leading to the identification of the association between GSTM3*B and 167 
a lower chance of cisplatin-induced ototoxicity in a small heterogeneous cancer cohort (n=39, 168 
of which 3 brain tumor patients).[30] These associations were never investigated in brain tumor 169 
patients only. Four studies, including one pathway approach study, investigated variants in the 170 
gene Megalin (LRP2), which was studied because of its known expression in the marginal cells 171 
of the stria vascularis in the inner ear.[33-36] The study by Riedemann et al. found an 172 
association between the A allele of LRP2 rs2075252 and a higher risk for development of 173 
ototoxicity in various pediatric cancer patients,[33] but this finding was not replicated by 174 
others.[34-36] Likewise, Choeyprasert et al. identified an association between LRP2 175 
rs2228171 and hearing loss, which was not in line results published in the other studies.[33-176 
36] 177 
Two newly investigated candidate genes, being SLC22A2 and SOD2, were found to be 178 
significantly linked to ototoxicity. Lanvers-Kaminsky et al. found the polymorphism SLC22A2 179 
rs316019 G>T to be a protective marker for hearing loss in 64 pediatric patients (of which 12 180 
brain tumor patients) and replicated this result in 66 adults with solid tumors.[37] The SLC22A2 181 
was studied because it encodes a transporter which is likely to be involved in cisplatin-induced 182 
oto- and nephrotoxicity.  A study by Brown et al. recently reported the C allele of SOD2 rs4880 183 
to be significantly associated with increased susceptibility to ototoxicity in 71 medulloblastoma 184 
and PNET patients.[38] Five variants in this candidate gene were investigated because of their 185 
association with platinum toxicity in renal epithelial cells and its relation with noise-induced 186 
hearing loss. Replication studies of the results for SLC22A2 and SOD2 have not been 187 
published to date.  188 
A pharmacogenetic study using a pathway approach was performed by Ross et al. in a cohort 189 
of 162 pediatric cancer patients, including 33 brain tumor patients.[35] The authors studied 190 
1,949 variants in 220 drug metabolizing genes. The variants TPMT rs12201199 and COMT 191 
rs9332377 were detected to be significantly associated with cisplatin-induced hearing loss. 192 
The association between TPMT rs12201199 and hearing loss was replicated in a cohort 193 
consisting of 155 additional pediatric cancer patients (of which 37 brain tumor patients). 194 
Combined analysis of both patient groups also lead to an additional identification of an 195 
association between ABCC3 rs1051640 and hearing loss.[39] However, the results of a study 196 
by Yang et al. were not in line with the previous findings, reporting no association of TPMT or 197 
COMT with ototoxicity, both in vitro (using mice with different TPMT genotypes) and in vivo 198 
(213 medulloblastoma patients).[40] Also, three recent publications were unable to detect 199 
associated variants in TPMT and COMT to cisplatin-induced hearing loss in brain tumor 200 
patients.[36, 41, 42] The conflicting results of these studies suggest that these genetic variants 201 
may not be suitable for clinical application. 202 
The only published GWAS in pediatric brain tumor patients so far was performed by Xu et al. 203 
in 2015. They investigated associations with 1,716,999 variants in 218 children with embryonal 204 
brain tumors, including 203 medulloblastoma patients.[41] The genetic variant rs1872328 in 205 
ACYP2 reached genome-wide significance, showing patients who were carrying of the A allele 206 
of this variant all developed hearing loss. Similar results were found in the replication cohort 207 
which included 68 brain tumor patients.   208 
 209 
Pharmacogenetics and vincristine-induced neurotoxicity 210 
The role of genetic variants in the response to vincristine are only investigated in three small 211 
scale candidate gene studies in cohorts consisting of patients with various pediatric cancers, 212 
including a handful of brain tumor patients (Table 3). The studies investigated genetic variants 213 
in ABCB1, CYP3A4 and CYP3A5, but they were unable to identify associations with vincristine 214 
pharmacokinetics and vincristine-induced neurotoxicity.[43-45]  215 
DISCUSSION  216 
This systematic review provides an overview of publications concerning pharmacogenetic 217 
research in pediatric medulloblastomas and low-grade gliomas, to evaluate existing evidence 218 
of the role of genetic variants to chemotherapy treatment outcome. As pharmacogenetics is 219 
poorly investigated in homogenous brain tumor populations, studies in pediatric solid tumor 220 
cohorts partially consisting of brain tumor patients were also reviewed. However, these results 221 
should be interpreted with caution, as interpatient variation concerning disease and treatment 222 
may be confounding variables for genetic association analysis, and thus may limit the 223 
predictive capacity of these variants in pediatric medulloblastomas and low-grade gliomas.  224 
A few studies investigated the influence of genetic variants on survival as an endpoint for 225 
treatment efficacy. As mentioned before, survival is not only determined by chemotherapy 226 
efficacy, and therefore, in contrast to drug-related adverse events, other (clinical) variants need 227 
to be taken in great consideration when interpreting such an endpoint. Well-defined cohorts 228 
are therefore very important. Members of the detoxifying family GST have been a point of 229 
interest in pharmacogenetic studies in brain tumor patients concerning survival.[27-29] These 230 
genes encode for enzymes which catalyse the conjugation of glutathione of multiple toxic 231 
chemicals, which leads to inactivation. In other words, high GST enzyme activity is associated 232 
with drug resistance, which may lead to lower treatment efficacy and, consequently, lower 233 
survival rates. The drugs known to be influenced by GST members include alkylating and 234 
platinum agents and their metabolites, but also the free radicals formed by chemotherapy and 235 
radiation.[46, 47] Despite this hypothesis, genetic variants in GST genes did not significantly 236 
influence OS and PFS investigated in studies in low-grade gliomas and medulloblastomas.[27-237 
29] One study included in this review did find a significant association between GST and 238 
survival. However the association was only present in the subgroup of anaplastic gliomas 239 
(WHO-classification grade III), which are treated with a different regimen compared to the brain 240 
tumors we focussed on.[27] Because of this difference, the results in anaplastic gliomas do 241 
probably not apply directly to low-grade gliomas and medulloblastomas.  242 
The majority of pharmacogenetic studies in brain tumor patients have focussed on cisplatin-243 
related ototoxicity. Cisplatin is a widely used chemotherapeutic agent in oncology, for 244 
treatment of e.g. pediatric brain tumors and osteosarcomas, and adult testicular, ovarian and 245 
non-small cell lung cancers.  Especially children are at great risk of developing cisplatin-246 
induced ototoxicity, which occurs in up to 60% of the pediatric patients.[48, 49] Brain tumor 247 
patients are even at higher risk, because the majority of these patients also receive cranial 248 
radiation, which is an additional risk factor for hearing loss.[50, 51] Because cisplatin is 249 
routinely used, numerous studies have appeared investigating prevention methods (e.g. 250 
medical interventions), as well as identification of clinical or genetic predictors to prevent this 251 
disabling side effect.[52] However to date, no upfront stratification methods for cisplatin-252 
induced ototoxicity are used in daily practise.  253 
Members of the GST family have not only been point of interest concerning their possible 254 
influence on treatment efficacy, but also their relation with cisplatin-induced ototoxicity. As 255 
mentioned earlier, GST enzymes are known to influence the level of drug resistance to 256 
platinum-based agents and have an effect on free radicals. Concerning ototoxicity, low GST 257 
activity is associated with low drug inactivation and thereby high levels of metabolites and free 258 
radicals, possibly leading to damage of the cochlea. One study in medulloblastoma patients 259 
reported that carriers of the G allele on position 105 in the coding sequence of GSTP1 have 260 
an increased risk of hearing loss after cisplatin treatment.[29] In contrast, Oldenburg et al. 261 
found an increased risk of ototoxicity in patient carrying the A allele in this GSTP1 variant in 262 
173 adult testicular cancer survivors.[53] Also, no associations with genetic variants in GSTP1 263 
were identified in three studies in pediatric solid cancers (including the pathway approach study 264 
by Ross et al.).[30, 35, 36] However, the majority of patients in these cohorts did not receive 265 
cranial radiation, which is a confounding factor for ototoxicity and, therefore, might influence 266 
the results of the genetic association analysis. The earlier mentioned GWAS, also performed 267 
in medulloblastomas patients, does not report this polymorphism to be associated with 268 
cisplatin-induced hearing loss.[41]  269 
A variant in the gene ACYP2 seems very promising to predict cisplatin induced hearing loss, 270 
which was discovered in a GWAS in medulloblastoma patients by Xu et al.[41] In this study, 271 
all patients carrying the A allele in rs1872328 developed hearing loss upon cisplatin treatment. 272 
The exact working mechanism of the variant is no elucidated yet, but ACYP2 is known to be 273 
expressed in the cochlea.[54] Nonetheless, this is in our view a promising candidate for clinical 274 
implementation as in our replication study in osteosarcoma patients, again all patients with the 275 
A allele developed hearing loss. These findings suggest that the variant might also be useful 276 
to predict cisplatin-induced hearing loss in other tumors treated with this agent.[55] 277 
Unfortunately, the frequency of the variant is not high, thus only a small part of the patients 278 
that have a high risk for hearing loss can be identified.  279 
The polymorphisms TPMT and COMT and their role in cisplatin-induced hearing loss have 280 
been extensively studied in pediatric oncology patients, including brain tumor patients. Due to 281 
inconsistent results of multiple study groups, the effect of these variants is still 282 
controversial.[35, 36, 39-42, 56] These inconsistencies could be a result of differences in for 283 
example audiometry or study population and thereby, findings are not generally applicable. In 284 
addition, the direct mechanism between these variants and ototoxicity is still unclear, which 285 
makes it difficult to value the findings thus far.   286 
The role of pharmacogenetics in vincristine, known for its high risk of neurotoxicity, is poorly 287 
investigated in brain tumor patients, despite the fact that it is often the reason for chemotherapy 288 
dose limitations in these patients. Pharmacogenetic studies to vincristine-induced toxicities 289 
have been more extensively performed in patients with ALL, leading to the identification of the 290 
relation between CYP3A5 and vincristine-induced neurotoxicity.[57, 58] However, other 291 
studies failed to confirm these findings,[26, 59, 60] including studies in solid tumors discussed 292 
in this review.[44, 45]  293 
Recently, a GWAS by Diouf et al. identified a polymorphism in the promoter region of the gene 294 
CEP72 associated with an increased risk on and severity of vincristine-related neurotoxicity in 295 
321 patients with ALL.[26] The results were backed-up with in vitro experiments showing an 296 
influence of CEP72 expression on the neurons and leukemia cells derived from human stem 297 
cells and their sensitivity to vincristine. These results were replicated in adult ALL patients, but 298 
no associations were found in a study in a Spanish cohort with pediatric ALL patients.[61, 62] 299 
However, the mentioned studies investigated neurotoxicity development during different 300 
treatment phases, being during the continuation and induction phase, respectively. To date, 301 
no publications focussing on CEP72 polymorphisms and its role in the development of 302 
vincristine-induced toxicities in brain tumor patients have appeared. Because it is hypothesised 303 
that the potential interaction between the germline CEP72 polymorphisms and vincristine is 304 
comparable in different cancer types, it would be very interesting to perform replication studies 305 
in other vincristine-treated malignancies, including brain tumors. Because vincristine is a 306 
widely used agent, this might lead to a broad clinical application of these findings. 307 
 308 
Concluding remarks 309 
This review revealed that the pharmacogenetic research area in brain tumors is mainly 310 
performed in heterogeneous pediatric cancer cohorts. In contrast to other pediatric 311 
malignancies including osteosarcoma and ALL [55, 63], the number pharmacogenetic studies 312 
in well-defined cohorts of exclusively brain tumor patients is poor. Without a homogeneous 313 
study population and validation of findings in a sufficiently large population, clinical 314 
implementation of pharmacogenetic results is not within reach yet. Though we believe that the 315 
ACYP2 and CEP72 genes are very good candidates to study in additional patient cohorts with 316 
the ultimate goal, after proper validation, implementation in the clinical setting. 317 
The majority of pharmacogenetic studies in brain tumors focused on one or a few candidate 318 
genes. A genome wide approach is an appropriate method to discover novel unexpected 319 
variants, but also to identify various variants which have limited effects on their own but 320 
together play a big role in final response to therapy.   The number of GWASs is lagging behind 321 
in the pediatric (brain) tumor population, considering the fact only one GWAS has been 322 
performed to date. This can probably be attributed to the small patient cohorts available for 323 
pharmacogenetic association studies. Large cohorts are required to create enough power to 324 
identify relevant variants using a GWAS, which emphasizes the need for national and 325 
international collaboration for brain tumor research. These homogeneous cohorts are not only 326 
needed for identification, but also for replication and (prospective) validation of associated 327 
genes, which are essential steps before clinical implementation is possible. In addition, the 328 
pharmacogenetic field is also moving to next generation sequencing to identify genetic variants 329 
or mutations linked to treatment outcome, for which large cohorts are even more essential. 330 
Sufficiently sized cohorts and large scale screening methods will result in more insight in 331 
interpatient treatment variability, and may lead to clinical application of pharmacogenetic 332 
knowledge. Preferably, genetic association results should be backed-up with functional studies 333 
to unravel the working mechanisms of the findings. Of course, not the complete spectrum of 334 
treatment outcome can be predicted by pharmacogenetics. Also tumor properties (e.g. somatic 335 
mutations or tumor methylation patterns) can be the reason for a poor outcome. Ultimately, 336 
these factors in combination with pharmacogenetics will enable optimal personalized treatment 337 
of pediatric brain tumor patients, which should be reflected in improved survival and less side-338 
effects.   339 
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Table 1: Characteristics of studies of treatment efficacy and toxicity in brain tumor patients 
 
First author[Ref] 
 
Year 
 
Study 
approach 
 
No. of 
MB/ 
LGG 
patients 
 
MB/ 
LGG 
 
Ethnic 
origin; 
nationality 
 
Gene(s) 
investigated 
 
Outcome 
measures 
 
Associated 
variant(s) 
 
(Possible) 
functional role of 
the genetic 
variant 
 
 
Okcu[27] 
 
2004 
 
Candidate 
gene 
approach 
 
n = 44  
(of 278) 
 
LGG 
 
Non-
Hispanic 
white; 
American 
 
GSTM1 
GSTT1 
GSTP1 
 
OS, toxicities  
 
None 
 
 
NA 
 
Barahmani[28] 
 
2008 
 
Candidate 
gene 
approach 
 
n = 42 
 
MB 
 
Hispanic, 
non-
Hispanic 
white, 
African 
American, 
unspecified; 
American 
 
 
GSTM1 
GSTT1  
 
PFS, toxicities, 
intellectual 
impairment 
 
GSTT1 null   
GSTM1 null  
 
Enzyme activity ↓ 
 
Rednam[29] 
 
2013 
 
Candidate 
gene 
approach 
 
n = 89 
(of 106) 
 
MB 
 
Non-
Hispanic 
white, 
Hispanic, 
other; 
American 
 
 
GSTP1 
 
PFS, OS, 
toxicities 
 
GSTP1 105 A>G  
 
Enzyme activity ↓ 
 
Jin[64] 
 
2016 
 
Candidate 
gene 
approach 
 
n = 147 
(of 269) 
 
LGG  
 
NS; 
Chinese 
 
IL4  
IL13  
IL10  
IL4R 
 
 
 
 
 
PFS, OS  
 
IL4R r1801275  
 
Unkown 
 Correa[65] 
 
2016 
 
Candidate 
gene 
approach 
 
n = 35 
(of 150) 
 
LGG 
 
Caucasian, 
other; 
American 
 
COMT 
BDNF 
DTNBP1 
 
Neuropsychogical 
test of attention, 
executive 
functions and 
memory 
 
COMT rs4680   
COMT rs16815 
COMT rs4646316 
COMT rs9332377 
COMT rs4646312 
COMT rs5993883 
COMT rs4818 
COMT rs5746847 
COMT rs6269 
BDNF 
rs11030104 
BDNF 
rs10767664 
BDNF 
rs10835210 
BDNF rs2030324  
DTNBP1 
rs742106  
 
 
Dopamine 
availability ↓ 
 
 
 
 
 
 
 
Neural repair ↓ 
 
 
 
Modulation of 
neurotransmitter 
systems 
Abbreviations: MB, medulloblastoma; LGG, low-grade glioma; OS, overall survival; PFS, progression-free survival; NA, not applicable; NS, 
not specified.  
 
 
 
 
Table 2: Characteristics of studies of cisplatin-induced ototoxicity in patients with brain tumors 
First author [Ref] Year Study approach No. of MB/ 
LGG 
patients 
MB/ 
LGG 
Ethnic 
origin; 
nationality 
Gene(s) 
investigated 
Associated 
variant(s) 
(Possible) 
functional role 
of the genetic 
variant 
 
Peters[30] 
 
2000 
 
Candidate gene 
approach 
 
n = 3  
(of 39)a 
 
MB 
 
NS; 
German 
 
GSTM1 
GSTM3  
GSTT1  
GSTP1 
GSTZ1 
 
 
GSTM3*B  
 
Enzyme activity ↑ 
 
Peters[31] 
 
2003 
 
Candidate gene 
approach 
 
 
n = 3  
(of 39)a 
 
MB 
 
NS; 
German 
 
Mutations in 
mtDNA 
 
None 
 
NA 
 
Knoll[32] 
 
2006 
 
Candidate gene 
approach 
 
n = 7  
(of 11)  
 
NS 
 
NS; NS 
 
GJB2  
SLC26A4 
MTRNR1 
MTTL1 
MTTS1 
 
 
None 
 
NA 
 
Riedemann[33] 
 
2007 
 
Candidate gene 
approach 
 
n = 5  
(of 50) 
 
MB 
 
NS; 
German 
 
LRP2 
 
LRP2 rs2075252  
 
Unknown 
 
Ross[35] 
 
2009 
 
Pathway 
approach 
 
n = 33  
(of 162) 
 
MB/LGG 
 
European, 
Indian, East 
Asian; 
Canadian 
 
 
220 drug 
metabolism 
genes 
 
TPMT rs12201199 
COMT rs9332377 
 
Unknown 
 
Choeyprasert[34] 
 
2012 
 
Candidate gene 
approach 
 
n = 9  
(of 68) 
 
MB/LGG 
 
NS; Thai 
 
GSTT1  
GSTM1  
LRP2 
 
 
 
 
GSTT1*1 
LRP2 rs2228171  
 
 
Enzyme activity ↓ 
Unknown 
 Yang[40] 
 
2013 
 
Candidate gene 
approach 
 
n = 213 
 
MB 
 
NS; 
American 
 
TPMT 
COMT 
 
 
None 
 
NA 
 
Pussegoda[39] 
 
2013 
 
Candidate gene 
approach 
 
n = 70  
(of 317) 
 
NS 
 
Caucasian, 
other; 
Canadian 
 
TPMT  
COMT  
ABCC3 
MTHFR 
VKORC1 
SLCO1A2 
 
 
TPMT rs12201199  
ABCC3 rs1051640 
 
 
Unknown  
Unknown 
 
 
Lanvers-
Kaminsky[42] 
 
2014 
 
Candidate gene 
approach 
 
 
n = 12 
 (of 63) 
 
NS 
 
NS; 
German 
 
TPMT  
COMT  
 
None 
 
NA 
 
Lanvers-
Kaminsky[37] 
 
2015 
 
Candidate gene 
approach 
 
 
n = 12  
(of 64) 
 
NS 
 
NS; 
German 
 
SLC22A2 
SLC31A1 
 
SLC22A rs316019  
 
Substrate affinity 
 
Xu[41] 
 
2015 
 
Genome-wide 
approach 
 
n = 203 (of 
238) 
 
MB 
 
NS; 
American 
 
1,716,999 
variants 
 
ACYP2 rs1872328 
 
Unknown 
 
 
 
Brown[38] 
 
2015 
 
Candidate gene 
approach 
 
n = 71  
 
 
MB 
 
Non-
Hispanic 
white, 
Hispanic, 
other; 
American 
 
SOD2 
 
SOD2 rs4880  
 
↑ Oxidative 
stress in cochlea 
 
Olgun[36] 
 
2016 
 
Candidate gene 
approach 
 
n = 6  
(of 72) 
 
MB 
 
NS; Turkey 
 
ERCC1  
GSTP1 
LRP2 
TPMT 
COMT 
 
 
None 
 
None 
a Studies by Peters et al.; same cohorts 
Abbreviations: MB, medulloblastoma; LGG, low-grade glioma; NA, not applicable; NS, not specified.  
Table 3: Characteristics of studies of vincristine-induced neurotoxicity in patients with brain tumors 
 
First author [Ref] 
 
Year 
 
Study 
approach 
 
No. of 
MB/ 
LGG 
patients 
 
MB/ 
LGG 
 
Ethnic 
origin; 
nationality 
 
Gene(s) 
investigated 
 
Outcome 
measures 
 
Associated 
variant(s) 
 
(Possible) 
functional 
role of the 
genetic 
variant 
 
 
Guilhaumou[43]  
 
2011 
 
Candidate 
gene 
approach 
 
n = 4  
(of 26)b 
 
MB/LGG 
 
 
NS; France  
 
 
ABCB1 
CYP3A4 
CYP3A5 
 
PK 
parameters  
 
 
None 
 
NA 
 
Guilhaumou[44] 
 
 
2011 
 
Candidate 
gene 
approach 
 
 
n = 4  
(of 26)b 
 
MB/LGG 
 
NS; France  
 
ABCB1 
CYP3A4 
CYP3A5 
 
Neurotoxicity 
events 
 
 
None 
 
NA 
 
Moore[45] 
 
2011 
 
Candidate 
gene 
approach 
 
n = 7  
(of 50) 
 
NS 
 
Caucasian, 
Hispanic, 
Asian, 
Pacific 
Islander, 
Australian 
Aboriginal; 
Australian 
 
 
CYP3A5  
 
Neurotoxicity 
 
None 
 
NA 
b Studies by Guilhaumou et al.; same cohorts 
Abbreviations: MB, medulloblastoma; LGG, low-grade glioma; NA, not applicable; NS, not specified; PK, pharmacokinetics. 
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ABBREVIATIONS 
ABC  ATP-binding cassette 
ACYP  Acylphosphatase 
ALL  Acute lymphoblastic leukemia 
COMT  Catechol-O-methyltransferase 
CYP    Cytochrome P450 
DPYD  Dihydropyrimidine dehydrogenase 
GST  Glutathione S-transferase  
GWAS  Genome-wide association study 
IL  Interleukin 
LGG  Low-grade glioma 
LPR  Low-density lipoprotein (Megalin) 
MB  Medulloblastoma 
NS  Not specified 
OR   Odds ratio 
OS   Overall survival 
PK  Pharmacokinetics 
PNET  Primitive neuro-ectodermal tumor  
SNP  Single-nucleotide polymorphism 
SLC   Solute carrier 
SOD  Superoxide dismutase  
TPMT  Thiopurine S-methyltransferase 
 
 
 
  
SUPPLEMENTARY 
Supplementary table 1: Search strategy for electronic databases  
Electronic databases searched MEDLINE, Embase, Cochrane Library  
General search strategy Keywords and, when available, MeSH-terms were used to draft 
a search strategy combining the following three elements: 
“Brain tumor”, “Chemotherapy” and “Genetics”. Synonyms and 
related terms were used when appropriate. To broaden the 
number of articles useful for this systematic review, the first 
search strategy was combined with a second strategy, 
consisting the elements “Cisplatin / Carboplatin / Vincristine / 
Cyclophosphamide / Etoposide / Lomustine”, “Genetics” and 
“Toxicity”. By leaving the disease component out of this 
strategy, studies with heterogeneous cohorts could be 
identified. These articles were manually screened for presence 
of brain tumor patients in their cohorts.  
Date of search 30th of October, 2016 
Search terms used*:  
((("Brain Neoplasms"[Mesh] OR "Medulloblastoma"[Mesh] OR "Glioma"[Mesh] OR 
"Astrocytoma"[Mesh] OR "Optic Nerve Glioma"[Mesh] OR "Oligodendroglioma"[Mesh] OR 
"Ganglioglioma"[Mesh] OR brain neoplasm*[Title/Abstract] OR brain cancer[Title/Abstract] OR brain 
tumor*[Title/Abstract] OR brain tumour*[Title/Abstract] OR medulloblastoma[Title/Abstract] OR 
glioma[Title/Abstract] OR astrocytoma[Title/Abstract] OR oligodendroglioma[Title/Abstract] OR 
ganglioglioma[Title/Abstract]) AND ("Drug Therapy"[Mesh] OR drug therapy[Title/Abstract] OR 
chemotherapy[Title/Abstract] OR "Vincristine"[Mesh] OR vincristine[Title/Abstract] OR 
"Cisplatin"[Mesh] OR cisplatin[Title/Abstract] OR "Carboplatin"[Mesh] OR carboplatin[Title/Abstract] 
OR "Cyclophosphamide"[Mesh] OR cyclophosphamide[Title/Abstract]) AND ("Genomic Structural 
Variation"[Mesh] OR  "Pharmacogenetics"[Mesh] OR "Polymorphism, Genetic"[Mesh] OR 
"Polymorphism, Single Nucleotide"[Mesh] OR "Genotype"[Mesh] OR "Germ-Line Mutation"[Mesh] 
OR genetic variant*[Title/Abstract] OR genetic variation*[Title/Abstract] OR gene 
variation*[Title/Abstract] OR gene variant*[Title/Abstract] OR polymorphism*[Title/Abstract] OR 
SNP[Title/Abstract] OR pharmacogenetic*[Title/Abstract] OR pharmacogenomic*[Title/Abstract] OR 
genotype*[Title/Abstract] OR variation*[Title/Abstract] OR variant*[Title/Abstract] OR genetic 
variability[Title/Abstract] OR germ-line mutation*[Title/Abstract] OR germ-line 
variation*[Title/Abstract])) OR (("Cisplatin"[Mesh] OR cisplatin[Title/Abstract]) AND ("Genomic 
Structural Variation"[Mesh] OR  "Pharmacogenetics"[Mesh] OR "Polymorphism, Genetic"[Mesh] OR 
"Polymorphism, Single Nucleotide"[Mesh] OR "Genotype"[Mesh] OR "Germ-Line Mutation"[Mesh] 
OR genetic variant*[Title/Abstract] OR genetic variation*[Title/Abstract] OR gene 
variation*[Title/Abstract] OR gene variant*[Title/Abstract] OR polymorphism*[Title/Abstract] OR 
SNP[Title/Abstract] OR pharmacogenetic*[Title/Abstract] OR pharmacogenomic*[Title/Abstract] OR 
genotype*[Title/Abstract] OR variation*[Title/Abstract] OR variant*[Title/Abstract] OR genetic 
variability[Title/Abstract] OR germ-line mutation*[Title/Abstract] OR germ-line 
variation*[Title/Abstract]) AND ("toxicity"[Subheading] OR "Drug-Related Side Effects and Adverse 
Reactions"[Mesh] OR toxicity[Title/Abstract] OR toxicities[Title/Abstract] OR side 
effect*[Title/Abstract] OR ototoxic*[Title/Abstract] OR hearing loss[Title/Abstract])) OR 
(("Carboplatin"[Mesh] OR carboplatin[Title/Abstract]) AND ("Genomic Structural Variation"[Mesh] 
OR  "Pharmacogenetics"[Mesh] OR "Polymorphism, Genetic"[Mesh] OR "Polymorphism, Single 
Nucleotide"[Mesh] OR "Genotype"[Mesh] OR "Germ-Line Mutation"[Mesh] OR genetic 
variant*[Title/Abstract] OR genetic variation*[Title/Abstract] OR gene variation*[Title/Abstract] OR 
gene variant*[Title/Abstract] OR polymorphism*[Title/Abstract] OR SNP[Title/Abstract] OR 
pharmacogenetic*[Title/Abstract] OR pharmacogenomic*[Title/Abstract] OR 
genotype*[Title/Abstract] OR variation*[Title/Abstract] OR variant*[Title/Abstract] OR genetic 
variability[Title/Abstract] OR germ-line mutation*[Title/Abstract] OR germ-line 
variation*[Title/Abstract]) AND ("toxicity"[Subheading] OR "Drug-Related Side Effects and Adverse 
Reactions"[Mesh] OR toxicity[Title/Abstract] OR toxicities[Title/Abstract] OR side 
effect*[Title/Abstract] OR ototoxic*[Title/Abstract] OR hearing loss[Title/Abstract])) OR 
(("Vincristine"[Mesh] OR vincristine[Title/Abstract]) AND ("Genomic Structural Variation"[Mesh] OR  
"Pharmacogenetics"[Mesh] OR "Polymorphism, Genetic"[Mesh] OR "Polymorphism, Single 
Nucleotide"[Mesh] OR "Genotype"[Mesh] OR "Germ-Line Mutation"[Mesh] OR genetic 
variant*[Title/Abstract] OR genetic variation*[Title/Abstract] OR gene variation*[Title/Abstract] OR 
gene variant*[Title/Abstract] OR polymorphism*[Title/Abstract] OR SNP[Title/Abstract] OR 
pharmacogenetic*[Title/Abstract] OR pharmacogenomic*[Title/Abstract] OR 
genotype*[Title/Abstract] OR variation*[Title/Abstract] OR variant*[Title/Abstract] OR genetic 
variability[Title/Abstract] OR germ-line mutation*[Title/Abstract] OR germ-line 
variation*[Title/Abstract]) AND ("toxicity"[Subheading] OR "Drug-Related Side Effects and Adverse 
Reactions"[Mesh] OR toxicity[Title/Abstract] OR toxicities[Title/Abstract] OR side 
effect*[Title/Abstract] OR “Polyneuropathies"[Mesh] OR polyneuropathy[Title/Abstract] OR 
neuropathy[Title/Abstract] OR neurotoxicity[Title/Abstract])) OR (("Cyclophosphamide"[Mesh] OR 
cyclophosphamide[Title/Abstract]) AND ("Genomic Structural Variation"[Mesh] OR  
"Pharmacogenetics"[Mesh] OR "Polymorphism, Genetic"[Mesh] OR "Polymorphism, Single 
Nucleotide"[Mesh] OR "Genotype"[Mesh] OR "Germ-Line Mutation"[Mesh] OR genetic 
variant*[Title/Abstract] OR genetic variation*[Title/Abstract] OR gene variation*[Title/Abstract] OR 
gene variant*[Title/Abstract] OR polymorphism*[Title/Abstract] OR SNP[Title/Abstract] OR 
pharmacogenetic*[Title/Abstract] OR pharmacogenomic*[Title/Abstract] OR 
genotype*[Title/Abstract] OR variation*[Title/Abstract] OR variant*[Title/Abstract] OR genetic 
variability[Title/Abstract] OR germ-line mutation*[Title/Abstract] OR germ-line 
variation*[Title/Abstract]) AND ("toxicity"[Subheading] OR "Drug-Related Side Effects and Adverse 
Reactions"[Mesh] OR toxicity[Title/Abstract] OR toxicities[Title/Abstract] OR side 
effect*[Title/Abstract]OR "Renal Insufficiency"[Mesh] OR "Kidney Failure, Chronic"[Mesh] OR 
nephrotoxic*[Title/Abstract] OR renal failure[Title/Abstract] OR kidney failure[Title/Abstract])) OR  
(("Etoposide"[Mesh] OR etoposide[Title]) AND ("Genomic Structural Variation"[Mesh] OR  
"Pharmacogenetics"[Mesh] OR "Polymorphism, Genetic"[Mesh] OR "Polymorphism, Single 
Nucleotide"[Mesh] OR "Genotype"[Mesh] OR "Germ-Line Mutation"[Mesh] OR genetic 
variant*[Title/Abstract] OR genetic variation*[Title/Abstract] OR gene variation*[Title/Abstract] OR 
gene variant*[Title/Abstract] OR polymorphism*[Title/Abstract] OR SNP[Title/Abstract] OR 
pharmacogenetic*[Title/Abstract] OR pharmacogenomic*[Title/Abstract] OR 
genotype*[Title/Abstract] OR variation*[Title/Abstract] OR variant*[Title/Abstract] OR genetic 
variability[Title/Abstract] OR germ-line mutation*[Title/Abstract] OR germ-line 
variation*[Title/Abstract]) AND ("toxicity"[Subheading] OR "Drug-Related Side Effects and Adverse 
Reactions"[Mesh] OR toxicity[Title/Abstract] OR toxicities[Title/Abstract] OR side 
effect*[Title/Abstract])) OR (("Lomustine"[Mesh] OR lomustine[Title]) AND ("Genomic Structural 
Variation"[Mesh] OR  "Pharmacogenetics"[Mesh] OR "Polymorphism, Genetic"[Mesh] OR 
"Polymorphism, Single Nucleotide"[Mesh] OR "Genotype"[Mesh] OR "Germ-Line Mutation"[Mesh] 
OR genetic variant*[Title/Abstract] OR genetic variation*[Title/Abstract] OR gene 
variation*[Title/Abstract] OR gene variant*[Title/Abstract] OR polymorphism*[Title/Abstract] OR 
SNP[Title/Abstract] OR pharmacogenetic*[Title/Abstract] OR pharmacogenomic*[Title/Abstract] OR 
genotype*[Title/Abstract] OR variation*[Title/Abstract] OR variant*[Title/Abstract] OR genetic 
variability[Title/Abstract] OR germ-line mutation*[Title/Abstract] OR germ-line 
variation*[Title/Abstract]) AND ("toxicity"[Subheading] OR "Drug-Related Side Effects and Adverse 
Reactions"[Mesh] OR toxicity[Title/Abstract] OR toxicities[Title/Abstract] OR side 
effect*[Title/Abstract]))) 
 
* The search terms used in MEDLINE are shown; comparable search terms were used for the other 
electronic databases.  
 
 
 
 
 
